Schering Betaseron Cleared For Secondary Progressive MS In EU
Executive Summary
Schering AG's interferon beta-1b product Betaseron/Betaferon has been cleared by the European Commission for use in patients with secondary progressive multiple sclerosis "to slow progression of disease and reduce the frequency of relapses," the firm announced Jan. 28.